Valganciclovir

Author: Prof. Dr. med. Peter Altmeyer

All authors of this article

Last updated on: 29.10.2020

Dieser Artikel auf Deutsch

Definition
This section has been translated automatically.

Indication
This section has been translated automatically.

Cytomegalovirus retinitis in patients with HIV infection (AIDS), prophylaxis of CMV disease in CMV negative patients who have received an organ transplant from a CMV positive donor.

Limited indication
This section has been translated automatically.

Renal insufficiency, dialysis patients, leukopenia, neutrocytopenia < 500/µl, thrombocytopenia < 25,000/µl, Hb < 8 g/dl.

Pregnancy/nursing period
This section has been translated automatically.

Contraindicated.

Dosage and method of use
This section has been translated automatically.

Initial: 2 times/day 900 mg p.o. for 21 days. Maintenance therapy: 900 mg once/day. Maintenance therapy and prophylaxis for organ transplant patients: 900 mg once a day. If the retinitis worsens, the dose may be increased as in initial therapy (risk of drug resistance exists!).

Undesirable effects
This section has been translated automatically.

Contraindication
This section has been translated automatically.

Use in patients < 18 years of age. Hypersensitivity to Aciclovir and Valaciclovir i.A.

Preparations
This section has been translated automatically.

Valcyte

Note(s)
This section has been translated automatically.

Remember! Damage to the genetic material is potentially possible. Therefore, men under treatment should not conceive a child 6 months after therapy. Women should use effective contraception during treatment!

Outgoing links (3)

Ganciclovir; Hiv infection; Virustatics;

Authors

Last updated on: 29.10.2020